Toll-like receptors promote inflammation in idiopathic inflammatory myopathies

Journal of Neuropathology and Experimental Neurology

Volumn 71, Issue 10, 2012, Pages 855-867

  Brunn, Anna ^a   Zornbach, Katja ^a   Hans, Volkmar H ^b   Haupt, Walter F ^c   Deckert, Martina ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b EVANGELISCHES KRANKENHAUS   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Dermatomyositis; Inclusion body myositis; MyD88; NF B; Polymyositis; Toll like receptors

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12P40; INTERLEUKIN 17; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATOMYOSITIS; HUMAN; HUMAN TISSUE; INCLUSION BODY MYOSITIS; INFLAMMATORY INFILTRATE; MUSCLE BIOPSY; MYOSITIS; NONINFLAMMATORY NEUROGENIC ATROPHY; POLYMYOSITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; VASCULITIS ASSOCIATED INTERSTITIAL MYOSITIS;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; INFLAMMATION; MIDDLE AGED; MYOSITIS; RNA, MESSENGER; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 9; TOLL-LIKE RECEPTORS; UP-REGULATION;

EID: 84866729256     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0b013e31826bf7f3     Document Type: Article

References (47)

1. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124:783-801
2. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011;34:637-50
3. Kumar H, Kawai T, Akira S. Toll-like receptors and innate immunity. Biochem Biophys Res Commun 2009;388:621-25
4. Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine 2008;42:145-51
5. Mansell A, Brint E, Gould JA, et al. Mal interacts with tumor necrosis factor receptorYassociated factor (TRAF)-6 to mediate NF-kappaB activation by toll-like receptor (TLR)-2 and TLR4. J Biol Chem 2004;279: 37227-30
6. Yamamoto M, Sato S, Mori K, et al. Cutting edge: A novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J Immunol 2002; 169:6668-72
7. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004;25:280-88 (Pubitemid 38610351)
8. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol 2005;17:1-14
9. Mason N, Aliberti J, Caamano JC, et al. Cutting edge: Identification of c-RelYdependent and Yindependent pathways of IL-12 production during infectious and inflammatory stimuli. J Immunol 2002;168:2590-94
10. Wysocka M, Kubin M, Vieira LQ, et al. Interleukin-12 is required for interferon-gamma production and lethality in lipopolysaccharide-induced shock in mice. Eur J Immunol 1995;25:672-76
11. Bsibsi M, Ravid R, Gveric D, et al. Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol 2002;61:1013-21
12. Jack CS, Arbour N, Manusow J, et al. TLR signaling tailors innate immune responses in human microglia and astrocytes. J Immunol 2005; 175:4320-30
13. Olson JK, Miller SD. Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol 2004; 173:3916-24
14. Farina C, Krumbholz M, Giese T, et al. Preferential expression and function of Toll-like receptor 3 in human astrocytes. J Neuroimmunol 2005;159:12-19
15. Stenzel W, Soltek S, Sanchez-Ruiz M, et al. Both TLR2 and TLR4 are required for the effective immune response in Staphylococcus aureusY induced experimental murine brain abscess. Am J Pathol 2008;172:132-45
16. Prinz M, Garbe F, Schmidt H, et al. Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J Clin Invest 2006;116:456-64
17. Marta M, Andersson A, Isaksson M, et al. Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis. Eur J Immunol 2008;38:565-75
18. Miranda-Hernandez S, Gerlach N, Fletcher JM, et al. Role for MyD88, TLR2 and TLR9 but not TLR1, TLR4 or TLR6 in experimental autoimmune encephalomyelitis. J Immunol 2011;187:791-804
19. Cheng C, Qin Y, Shao X, et al. Induction of TNF-Alpha by LPS in Schwann cell is regulated by MAPK activation signals. Cell Mol Neurobiol 2007;27:909-21
20. Lee H, Jo EK, Choi SY, et al. Necrotic neuronal cells induce inflammatory Schwann cell activation via TLR2 and TLR3: Implication in Wallerian degeneration. Biochem Biophys Res Commun 2006;350:742-47
21. Oliveira RB, Ochoa MT, Sieling PA, et al. Expression of Toll-like receptor 2 on human Schwann cells: A mechanism of nerve damage in leprosy. Infect Immun 2003;71:1427-33
22. Goethals S, Ydens E, Timmerman V, et al. Toll-like receptor expression in the peripheral nerve. Glia 2010;58:1701-9
23. Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 1991;325:1487-98
24. Grundtman C, Malmstrom V, Lundberg IE. Immune mechanisms in the pathogenesis of idiopathic inflammatory myopathies. Arthritis Res Ther 2007;9:208
25. Ishii W, Matsuda M, Shimojima Y, et al. Flow cytometric analysis of lymphocyte subpopulations and TH1/TH2 balance in patients with polymyositis and dermatomyositis. Intern Med 2008;47:1593-99
26. Aleksza M, Szegedi A, Antal-Szalmas P, et al. Altered cytokine expression of peripheral blood lymphocytes in polymyositis and dermatomyositis. Ann Rheum Dis 2005;64:1485-89
27. Brunn A, Utermohlen O, Sanchez-Ruiz M, et al. Dual role of B cells with accelerated onset but reduced disease activity in P0(106-125)-induced experimental autoimmune neuritis of IgH (0/0) mice. Acta Neuropathol 2010;120:667-81
28. Frericks M, Esser C. A toolbox of novel murine house-keeping genes identified by meta-Analysis of large scale gene expression profiles. Biochim Biophys Acta 2008;1779:830-37
29. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-Time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402-8 (Pubitemid 34164012)
30. Brunn A, Hans VJ, Vogelgesang S, et al. Inflammatory myopathy with abundant macrophages and dermatomyositis: Two stages of one disorder or two distinct entities? Acta Neuropathol 2009;118:793-801
31. Lin AC, Dissanayake D, Dhanji S, et al. Different toll-like receptor stimuli have a profound impact on cytokines required to break tolerance and induce autoimmunity. PloS One 2011;6:e23940
32. Fang J, Fang D, Silver PB, et al. The role of TLR2, TRL3, TRL4, and TRL9 signaling in the pathogenesis of autoimmune disease in a retinal autoimmunity model. Invest Ophthalmol Vis Sci 2010;51:3092-99
33. Park MK, Oh HJ, Heo YM, et al. Myeloid differentiation primary response protein 88 blockade upregulates indoleamine 2,3-dioxygenase expression in rheumatoid synovial fibroblasts. Exp Mol Med 2011;43: 446-54
34. Leadbetter EA, Rifkin IR, Hohlbaum AM, et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002;416:603-7 (Pubitemid 34406754)
35. Wong CK, Wong PT, Tam LS, et al. Activation profile of Toll-like receptors of peripheral blood lymphocytes in patients with systemic lupus erythematosus. Clin Exp Immunol 2010;159:11-22
36. Marsland BJ, Nembrini C, Grun K, et al. TLR ligands act directly upon T cells to restore proliferation in the absence of protein kinase C-Theta signaling and promote autoimmune myocarditis. J Immunol 2007;178: 3466-73
37. Kim GT, Cho ML, Park YE, et al. Expression of TLR2, TLR4, and TLR9 in dermatomyositis and polymyositis. Clin Rheumatol 2010;29:273-79
38. Kaisho T, Takeuchi O, Kawai T, et al Endotoxin-induced maturation of MyD88-deficient dendritic cells. J Immunol 2001;166:5688-94
39. Yamamoto M, Sato S, Hemmi H, et al Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003;301:640-43
40. Akira S, Takeda K. Toll-like receptor signaling. Nature reviews. Immunology 2004;4:499-511
41. Cappelletti C, Baggi F, Zolezzi F, et al. Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies. Neurology 2011;76:2079-88 42. Re F, Strominger JL. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J Biol Chem 2001;276:37692-99
42. Eriksson U, Ricci R, Hunziker L, et al. Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nature medicine 2003;9:1484-90
43. Gonnella PA, Waldner H, Del Nido PJ, et al. Inhibition of experimental autoimmune myocarditis: Peripheral deletion of TcR Vbeta 8.1, 8.2+ CD4+ T cells in TLR-4-deficient mice. J Autoimmun 2008;31:180-87
44. Hodgkinson L. Digestive Disease Week 2010. Turning science into medicineVpart 2. IDrugs 2010;13:424-26
45. Liu Y, Zhang Z, Wang L, et al. TLR4 monoclonal antibody blockade suppresses dextran-sulfate-sodiumYinduced colitis in mice. J Gastroenterol Hepatol 2010;25:209-14
46. Hultqvist M, Nandakumar KS, Bjorklund U, et al. The novel small molecule drug Rabeximod is effective in reducing disease severity of mouse models of autoimmune disorders. Ann Rheum Dis 2009;68:130-35
47. Hultqvist M, Nandakumar KS, Bjorklund U, et al. Rabeximod reduces arthritis severity in mice by decreasing activation of inflammatory cells. Ann Rheum Dis 2010;69:1527-32